CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02689336
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:35.315530+00:00
Published At: 2019-09-09T00:00:00+00:00
Record Updated At: 2019-09-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Glioma", "Rhabdomyosarcoma", "Osteosarcoma", "Medulloblastoma", "Neuroectodermal Tumor", "Ependymoma", "Ewing\u0027s Sarcoma", "Wilms Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-09-09"
protocolSection.identificationModule.nctId: "NCT02689336"
protocolSection.identificationModule.officialTitle: "Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.